Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INDVNYSE:MED On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDVIndivior$14.13+1.7%$11.30$7.33▼$16.98$1.95B0.661.10 million shs461,010 shsMEDMedifast$13.36+2.9%$13.02$11.57▼$22.66$147.63M0.88271,367 shs51,176 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDVIndivior0.00%-1.28%+22.49%+39.04%-15.97%MEDMedifast0.00%+2.48%-7.16%-9.47%-34.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINDVIndivior2.5698 of 5 stars1.65.00.00.03.41.71.9MEDMedifast3.8727 of 5 stars3.02.00.02.01.71.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINDVIndivior 3.25Buy$15.006.16% UpsideMEDMedifast 2.00Hold$16.5023.52% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINDVIndivior$1.17B1.67$2.86 per share4.94N/A∞MEDMedifast$543.45M0.27$2.74 per share4.88$19.21 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINDVIndivior$2M-$0.31N/A8.26N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)MEDMedifast$99.42M-$0.6574.628.73N/A0.35%10.64%7.57%8/4/2025 (Estimated)Latest CSRT, IDH, MED, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/28/2025Q1 2025MEDMedifast-$0.07-$0.11-$0.04-$0.07$114.85 million$115.73 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINDVIndiviorN/AN/AN/AN/AN/AMEDMedifast$6.6049.41%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINDVIndiviorN/A0.830.65MEDMedifastN/A3.342.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINDVIndivior60.33%MEDMedifast95.51%Insider OwnershipCompanyInsider OwnershipINDVIndiviorN/AMEDMedifast2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINDVIndivior1,164137.88 millionN/ANot OptionableMEDMedifast87010.99 million10.67 millionOptionableCSRT, IDH, MED, and INDV HeadlinesRecent News About These CompaniesIs Medifast Gaining or Losing Market Support?June 13 at 4:51 PM | benzinga.com1 Safe-and-Steady Stock on Our Watchlist and 2 to QuestionJune 13 at 8:23 AM | msn.comShort Interest in Medifast, Inc. (NYSE:MED) Expands By 21.7%June 4, 2025 | marketbeat.comMondelez (MDLZ) Down 2.2% Since Last Earnings Report: Can It Rebound?May 30, 2025 | msn.comMedifast, Inc. (NYSE:MED) Shares Bought by Two Sigma Investments LPMay 30, 2025 | marketbeat.comMedifast, Inc. (NYSE:MED) Stock Holdings Reduced by Bank of America Corp DEMay 30, 2025 | marketbeat.comMedifast (MED) Up 10.9% Since Last Earnings Report: Can It Continue?May 28, 2025 | zacks.comTwo Sigma Advisers LP Grows Position in Medifast, Inc. (NYSE:MED)May 28, 2025 | marketbeat.comPersonal Care Stocks Q1 In Review: Medifast (NYSE:MED) Vs PeersMay 27, 2025 | msn.comZacks Research Has Pessimistic View of Medifast Q2 EarningsMay 24, 2025 | marketbeat.comJane Street Group LLC Sells 50,172 Shares of Medifast, Inc. (NYSE:MED)May 19, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 22,902 Shares of Medifast, Inc. (NYSE:MED)May 18, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 19,719 Shares of Medifast, Inc. (NYSE:MED)May 16, 2025 | marketbeat.comMED Q1 Earnings Call: Revenue Misses, Coach Productivity and GLP-1 Strategy in FocusMay 12, 2025 | finance.yahoo.comIs Medifast’s Revenue Decline Changing Its Earnings Per Share Trajectory?May 2, 2025 | kalkinemedia.comEarnings Release: Here's Why Analysts Cut Their Medifast, Inc. (NYSE:MED) Price Target To US$15.00May 2, 2025 | finance.yahoo.comMedifast First Quarter 2025 Earnings: EPS Beats ExpectationsMay 1, 2025 | finance.yahoo.comMedifast’s Earnings Call: Mixed Sentiment Amid ChallengesApril 29, 2025 | tipranks.comMedifast, Inc. (NYSE:MED) Q1 2025 Earnings Call TranscriptApril 29, 2025 | msn.comMedifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/YApril 29, 2025 | zacks.comQ1 2025 Medifast Inc Earnings CallApril 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWorkday Stock Price Implosion: An Automatic Buy for AI InvestorsBy Thomas Hughes | May 26, 2025View Workday Stock Price Implosion: An Automatic Buy for AI InvestorsIntel Refocuses: NEX Sale and Foundry Pivot Signal New EraBy Jeffrey Neal Johnson | May 21, 2025View Intel Refocuses: NEX Sale and Foundry Pivot Signal New EraWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May3 Medical Technology Stocks Outperforming in 2025By Ryan Hasson | June 9, 2025View 3 Medical Technology Stocks Outperforming in 2025CSRT, IDH, MED, and INDV Company DescriptionsIndivior NASDAQ:INDV$14.13 +0.24 (+1.72%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Medifast NYSE:MED$13.36 +0.38 (+2.91%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
